Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas by Menyhart, Otilia et al.
REVIEW Open Access
Molecular markers and potential
therapeutic targets in non-WNT/non-SHH
(group 3 and group 4) medulloblastomas
Otília Menyhárt1,2, Felice Giangaspero3,4 and Balázs Győrffy1,2*
Abstract
Childhood medulloblastomas (MB) are heterogeneous and are divided into four molecular subgroups. The
provisional non-wingless-activated (WNT)/non-sonic hedgehog-activated (SHH) category combining group 3 and
group 4 represents over two thirds of all MBs, coupled with the highest rates of metastases and least understood
pathology. The molecular era expanded our knowledge about molecular aberrations involved in MB tumorigenesis,
and here, we review processes leading to non-WNT/non-SHH MB formations.
The heterogeneous group 3 and group 4 MBs frequently harbor rare individual genetic alterations, yet the
emerging profiles suggest that infrequent events converge on common, potentially targetable signaling pathways.
A mutual theme is the altered epigenetic regulation, and in vitro approaches targeting epigenetic machinery are
promising. Growing evidence indicates the presence of an intermediate, mixed signature group along group 3 and
group 4, and future clarifications are imperative for concordant classification, as misidentifying patient samples has
serious implications for therapy and clinical trials.
To subdue the high MB mortality, we need to discern mechanisms of disease spread and recurrence. Current
preclinical models do not represent the full scale of group 3 and group 4 heterogeneity: all of existing group 3 cell
lines are MYC-amplified and most mouse models resemble MYC-activated MBs. Clinical samples provide a wealth of
information about the genetic divergence between primary tumors and metastatic clones, but recurrent MBs are
rarely resected. Molecularly stratified treatment options are limited, and targeted therapies are still in preclinical
development. Attacking these aggressive tumors at multiple frontiers will be needed to improve stagnant survival
rates.
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Introduction
Medulloblastoma (MB) is the most common pediatric
brain tumor [1], with a culminating incidence among chil-
dren before the age of five [2]. Unfortunately, disease dis-
semination is an early event, and as many as 40% of
patients carry metastases already at diagnosis [3], with a
grim outlook for survival [4]. Metastatic disease and
tumor recurrence are responsible for the stagnant survival
rates of the past decades [1, 2], while survivors frequently
face treatment-related adverse effects [1].
The current consensus agrees upon four distinct molecu-
lar entities within MBs: wingless-activated (WNT), sonic
hedgehog-activated (SHH), group 3, and group 4 MBs [5],
each characterized by specific mutations, copy number al-
terations, transcriptomic/methylomic profiles, and clinical
outcomes [6–9]. Subgroup assignment is prognostic with
markedly different survival rates; a 5-year overall survival
(OS) is as high as 95% in WNT, while group 3 patients fea-
ture the worst (45–60%), with the shortest survival among
infants. An intermediate (75–80%) OS characterizes group
4 and SHH MBs, although it also depends on histology,
presence of metastases, and molecular abnormalities such
as mutations and oncogene amplifications [10–14].
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Group 3 and group 4 MBs are more related to each
other than to WNT and SHH and appear as non-WNT/
non-SHH in the revised 2016 WHO classification [15],
yet they are molecularly and clinically heterogeneous
with diverse outcomes [16–18]. The provisional
non-WNT/non-SHH category presents a complex chal-
lenge as these tumors represent over two thirds of all
MBs, coupled with the highest rates of disseminated dis-
ease and least understood pathology.
Here we aim to summarize the present state of
non-WNT/non-SHH MB research, with a particular
focus on molecular similarities and differences between
group 3 and group 4 MBs.
Clinical attributes of group 3 and group 4 MBs
The demography of group 3 or group 4 MB patients
overlaps although the subtypes are associated with radic-
ally different prognosis and clinical outcome.
Group 3 MBs account for approximately 25% of all
cases, predominantly among infants and children, with a
peak diagnosis between ages 3 and 5 years and almost
never in adults; hence, in adults, only three MB sub-
groups can be differentiated [19, 20] (Fig. 1). The
male-to-female ratio is approximately two to one [12].
Group 3 MBs are the deadliest of all molecular sub-
groups, with a 58% 5-year OS in children and a 45%
5-year OS in infants [10, 16, 21]. The grim outcome re-
sults from the aggregation of adverse prognostic factors,
such as young age or presence of metastases (in up to
50% of patients) at diagnosis, large cell/anaplastic (LCA)
histology, and MYC amplification. Group 3 is most likely
to consist of multiple subcategories, out of which
MYC-amplified tumors confer an especially short sur-
vival; only 20% of these patients survive up to 5 years
[18, 22]. Group 3 MBs rarely recur at the original tumor
site, but reappear as metastases [23]. The rate of metas-
tasis does not necessarily reflect survival [12]; thus, chil-
dren with group 3 disease without disease spread who
are assigned to be standard-risk may face undertreat-
ment [10]. Targeted treatments are not yet developed for
group 3 patients due to our limited understanding of
tumorigenesis.
Group 4MB is the most prevalent biological subtype,
comprising approximately 40% of all MB patients, pre-
dominantly between ages 3 and 16 years, and yet, its
pathogenesis is the least understood [5, 10]. Very few in-
fants, approximately 45% of childhood and 25% of adult
cases, belong to this subgroup (Fig. 1), and it is three times
more frequent in males than in females across all age
groups [5, 10]. The prognosis for group 4 patients is inter-
mediate, and the 5-year survival reaches 80% when treated
with standard therapy [13], although non-metastatic
group 4 patients with chromosome 11 loss have an excel-
lent prognosis, with > 90% survival [8]. Approximately
30–40% of group 4MB patients have metastases at diag-
nosis and are currently treated as high risk, including
Fig. 1 Molecular subgroups of medulloblastoma. The current consensus divides medulloblastoma into four subgroups: WNT-activated (WNT),
SHH-activated (SHH), group 3, and group 4. Only the most frequently altered genes are listed for group 3 and group 4 (a). Adult samples are
extremely rare among group 3 patients, while the majority of group 4 tumors consist of children (b)
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those with an LCA histology. The 5-year survival of
high-risk patients is approximately 60% [8, 10, 14]. Adults
with group 4 MBs have a significantly worse prognosis
compared to the SHH- or WNT-activated subtypes [19].
Molecular identification of group 3 and group 4
MBs
The 2016 WHO classification refers to MB subgroups as
genetically defined variants with prognostic value and treats
group 3 and group 4 MBs as provisional entities. The rec-
ommendation integrates histological and molecular classifi-
cations, with different prognosis for classical or LCA
histology, the latter usually associated with a high-risk dis-
ease (although extremely rare in group 4) [15].
Initially, immunohistochemistry (IHC)-based markers
were developed to allocate molecular subgroup identity
to clinical samples. A diagnostic method involving a dis-
tinct set of antibodies (GAB1, β-catenin, filamin A, and
YAP1) distinguished WNT- and SHH-activated and
non-WNT/non-SHH MB subgroups in FFPE samples
[24]. Another four-antibody approach to identify sub-
groups also from FFPE samples included DKK1 for
WNT, SFRP1 for SHH, NPR3 for group 3, and KCNA1
for group 4 MBs, allocating 98% of samples into each
subcategory [12]. Nevertheless, subgroup assignment
solely based on IHC is not recommended any longer:
patchy nuclear β-catenin accumulation might be mis-
leading [25, 26] and validation studies revealed KCNA1
expression in all subgroups, making it unsuitable for clas-
sification [27]. Suboptimal reproducibility of IHC results
arising from different protocols, institutional standards,
and interpretations arrange for inconsistencies [25].
Identification of group 3 and group 4 MBs should be
based on either methylation or transcriptional profiling to
identifying samples clustering with other tumors of the
same type [8, 25]. Transcription may be assessed by either
genome-wide transcriptomics or specific gene panels, for
instance, the NanoString 22 gene signature. The assay
evaluates group 3 identity utilizing the expression of
IMPG2, GABRA5, EGFL11, NRL, MAB21 L2, and NPR3,
while allocates group 4 tumors based on KCNA1, EOMES,
KHDRBS2, RBM24, UNC5D, and OASI expression [28].
The methylation- or transcriptional profiling-based classi-
fications are robust, although their implementation might
be challenging in the daily practice.
A clinically applicable rapid approach classified
non-WNT/non-SHH MBs with 92% accuracy based on
highly specific epigenetic biomarkers from both fresh frozen
and FFPE samples. The differentially methylated CpG
probes were located within an intergenic region of chromo-
some 12, the intronic regions of RPTOR and RIMS2, and
the 3′-UTR region of VPS37B genes. The method accur-
ately classified unambiguous group 3 and group 4 cases,
however demonstrated limited discrimination capacity with
tumors harboring intermediate methylation profiles [29].
MBs with ambiguous subgroup identity
A growing number of studies suggest that subgroups
within non-WNT/non-SHH tumors should be explored
further to capture patient diversity. A large-scale study
utilizing methylomic data revealed a shared biological
signature between group 3 and group 4 tumors, suggest-
ing a likelihood of common origin. Combining the two
subgroups, especially low-risk group 3 and group 4 sam-
ples for clinical purposes, results in a categorization out-
performing the current risk stratification models [30]
(Fig. 2a and 3a). Integration of methylomic and tran-
scriptomic data found ambiguous subgroup identity in
3% of samples [31]. Gene expression-based clustering
also identified non-WNT/non-SHH subtypes with mixed
signatures [18, 32]. The ambiguity of categorization has
been reflected in established MB cell lines: D283 cells
have been categorized in the past as both group 3 [33]
and group 4 [34] and, along with the D721 cell line, ex-
press high levels of both MYC and OTX2 mRNA. These
cell lines were placed eventually to an intermediate cat-
egory [35].
Three MB subgroups within non-WNT/non-SHH
tumors were recently described: group 3, group 4,
and intermediate group 3/4 MBs, the latter with re-
markably good prognosis [36]. Although based on a
limited sample size, the results imply that provisional
group 3 and group 4 distinctions could misplace a
portion of patients. The study extended the Nano-
String 22 gene signature [28] further, including the
expression of SNCAIP, MYCC, RCVRN, and PDC
genes. Future clarifications ought to standardize the
methods for diagnostic purposes as patient misclassifi-
cation has serious implications for treatment and en-
rollment into clinical trials.
Molecular biology of group 3 and group 4 MBs
Genetic predispositions
Damaging germline mutations in known cancer predis-
position genes is rare in non-WNT/non-SHH MB
pediatric patients. In a sample of 1022 MBs, germline
BRCA2 and PALB2 mutations were present in 1–2% of
group 3/group 4 tumors, associated with mutational sig-
natures typical of homologous recombination repair
(HR) deficiency. Occasional heterozygous germline
FANCA (n = 1, group 3) or FANCQ (n = 1, group 4) mu-
tations were also identified and linked to an
HR-deficiency mutation spectrum. Genetic testing for
these patients is recommended in case of a familial his-
tory of BRCA-associated cancers or if mutational signa-
tures are suggestive of HR deficiency [37].
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Recurrent somatic driver events
Group 3 and group 4 MBs are genetically heterogeneous
and, unlike WNT and SHH-activated MBs, are not
driven by well-defined, constitutively activated signaling
pathways. Tetraploidy is a recurrent early genetic event
in both group 3 and group 4 MBs, leading to an in-
creased number of large-scale copy number gains [38].
A meta-analysis based on 550 samples identified a gain
of 17q (in 58% of samples) and loss of 17p (55%) along
with a loss of 16q (42%), 10q (43%), and 9q (21%) and
gain of 7 (39%) and 1q (41%) as most recurrent struc-
tural aberrations in Group 3 MBs [10] (Table 1). Tetra-
ploidy also occurs early in approximately 40% of group 4
tumors [38], but its prognostic significance is yet un-
clear. Isochromosome 17q (a chromosome with two
17q arms) is present in about 80% of all group 4 samples
but is not predictive of outcome. Chromosome 7 gain
(47%), 8p loss (41%), 10q loss (15%), and 11p and 18q
aberrations are also regular events (Table 2). Approxi-
mately 80% of females have a complete loss of one X
chromosome [10, 12, 18, 39]. Both group 3 and group 4
MBs harbor frequent chromosomal aberrations although
somatic mutations are relatively infrequent. In fact, more
than half of group 3 samples are thought to be devoided
of mutations; based on deep sequencing of 92 samples,
none of the 12 most significantly mutated genes were al-
tered in group 3 and group 4 tumors [21, 40].
Somatic MYC (17% in group 3) and MYCN (6% in
group 4) amplifications are the most frequently observed
driver events [28]. The link between MYC and group 3
MB outcome is well established, and high MYC levels
are associated with significantly reduced survival [18,
41]. MYC activation develops because of amplification at
the MYC loci, genomic rearrangement of PVT1–MYC,
or other yet-unknown mechanisms [22, 28, 42–44].
Recently, a study with a large sample size identified at
least one potential driver events in 76% of group 3 and
82% of group 4 MBs, with an almost equal occurrence
of MYCN amplifications across group 3 (5%) and group
4 (6%), with MYC amplifications restricted to group 3
Fig. 2 Risk stratification, proposed prognostic biomarkers, and major mechanisms of tumorigenesis in group 3 medulloblastomas (a). Schematic
representation of major mechanisms most frequently affected by somatic alterations within group 3 tumors contributing to medulloblastoma
development (b). LR, low risk; HR, high risk
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tumors (17%) [6]. Activation of the mutually exclusive
GFI1/GFI1B was identified as the most prevalent driver
event through “enhancer hijacking”, by depositing them
near active regulatory elements. Hotspot insertions tar-
geting a novel potential oncogene, KBTBD4, were also
frequent both in group 3 and group 4 samples [6, 38].
The prognostic significance of GFI1/GFI1B activation is
not yet clear [45], although a large-scale integrative ana-
lysis of gene expression and methylation data indicated
the presence of GFI1/GFI1B activations mainly within a
particular subtype of group 3 tumors [31].
A single copy gain of the SNCAIP gene is present in
over 10% of group 4 tumors and represents the most
distinctly upregulated gene within the group 4 signature.
SNCAIP is involved in the development of Parkinson’s
disease, and its tandem duplications in group 4 MBs are
mutually exclusive with MYCN and CDK6 amplifica-
tions, the latter present in 5–10% of all group 4 tumors
[18, 28]. In group 4 MBs, PRDM6, an epigenetic
regulator of gene activity, is the probable target of
SNCAIP-associated enhancer hijacking and is activated
in about 17% of tumors [6].
SMARCA4 encoding subunits of the SWI/SNF-like
chromatin-remodeling complex is among the most re-
currently (~ 9%) mutated genes in group 3 tumors [6, 38].
Network analysis of group 4 somatic copy number aberra-
tions revealed the enrichment of genes responsible for
chromatin modification and identified a novel homolo-
gous deletion of a histone-lysine demethylase, KDM6A
[28], that preferentially demethylates the H3K27 trimethyl
mark (H3K27me3) [46]. Somatic mutations of the
KDM6A gene are exclusively present in approximately
12% of group 4 tumors, along with frequent mutations of
other 6 KDM family members (KDM1A, KDM3A,
KDM4A, KDM5A, KDM5B, and KDM7A) [21, 38, 40, 47]
(Table 2). EZH2 is also amplified or overexpressed in
group 3 and 4 tumors, contributing to the inscription of
H3K27me3, and is mutually exclusive with KDM6A
Fig. 3 Risk stratification, proposed prognostic biomarkers, and major mechanisms of tumorigenesis in group 4 medulloblastomas (a). Schematic
representation of major mechanisms most frequently affected by somatic alterations within group 4 MBs contributing to medulloblastoma
development (b). LR, low risk; HR, high risk
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Table 1 Frequent genetic alterations in group 3 MBs according to [6, 12, 28, 38, 40, 113]
Percentage
of patients
Gene/
chromosome
Modification Gene name Gene
location
Gene function
58 17q Mainly gain – – –
55 17p Mainly loss – – –
55 8q Gain or loss – – –
51 8p Gain or loss – – –
48 7q Mainly gain – – –
43 10q Mainly loss – – –
42 16q Mainly loss – – –
41 1q Mainly gain – – –
39 7p Mainly gain – – –
38 13q Gain or loss – – –
34 11q Mainly loss – – –
32 11p Mainly loss – – –
31 5q Mainly gain – – –
30 5p Mainly gain – – –
21 X Loss – – –
17 MYC Amplification,
overexpression
MYC proto-oncogene, bHLH transcription
factor
8q24.21 Transcriptional regulation
12 PVT1 Amplification Pvt1 oncogene (non-protein coding) 8q24.21 Oncogenic lncRNA
11 GFI1B overexpression,
amplification,
deletion
Growth factor independent 1B transcriptional
repressor
9q34.13 Transcriptional regulation
9 SMARCA4 Mutation SWI/SNF-related, matrix-associated, actin-dependent
regulator of chromatin, subfamily a, member 4
19p13.2 Chromatin modulation, SWI/SNF
Nucleosome-remodeling complex
6 KBTBD4 Mutation Kelch repeat and BTB domain containing 4 11p11.2 Ubiquitination of target
substrates
6 SHPRH Low level
amplification
SNF2 histone linker PHD RING helicase 6q24.3 Genome maintenance
5 CD109 Deletion CD109 molecule 6q13 TGF-β signaling
5 CTDNEP1 Mutation CTD nuclear envelope phosphatase 1 17p13.1 Metabolism of fatty acids
5 KMT2D Mutation Lysine methyltransferase 2D 12q13.12 Chromatin modulation
5 KDM7A Mutation Lysine demethylase 7A 7q34 Chromatin modulation
5 CHD7 Mutation Chromodomain helicase DNA binding protein 7 8q12.2 Chromatin modulation
5 DDX3X Mutation DEAD-box helicase 3, X-linked Xp11.4 RNA metabolism
5 KDM3A Mutation Lysine demethylase 3A 2p11.2 Chromatin modulation
5 KDM4C Mutation Lysine demethylase 4C 9p24.1 Chromatin modulation
5 KDM5B Mutation Lysine demethylase 5B 1q32.1 Chromatin modulation
5 KDM6A Mutation Lysine demethylase 6A Xp11.3 Chromatin modulation
5 MYCN Amplification MYCN proto-oncogene, bHLH transcription factor 2p24.3 Transcriptional regulation
5 CREBBP Amplification CREB binding protein 16p13.3 Chromatin modulation,
transcription initiation
5 DDX31 Amplification DEAD-box helicase 31 9q34.13 RNA metabolism
4 ESRRG Low level
amplification
Estrogen-related receptor gamma 1q41 Transcriptional regulation,
estrogen signaling
4 SNX6 Deletion Sorting nexin 6 14q13.1 TGF-β signaling
4 GFI1 Overexpression,
amplification
Growth factor independent 1 transcriptional
repressor
1p22.1 Transcriptional regulation
3 OTX2 Amplification, Orthodenticle homeobox 2 14q22.3 Transcriptional regulation
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mutations. About 50% of tumors with KDM6A and
KDM1A mutations also harbor ZMYM3 mutations, sug-
gesting a cooperation between these two genes [47]. The
relatively numerous CHD7 or ZMYM3 mutations partake
in the regulation of the H3K4me3 mark [6]. Inactivating
mutations in MLL2 and MLL3 genes also participate in
the reduction of H3K4me3 levels, promoting the deactiva-
tion of prodifferentiation genes [38, 48]. TBR1 and
EOMES expression is significantly higher in group 3 and 4
tumors compared to other subgroups and strongly corre-
lates with gene methylation [38]. These observations sug-
gest that by preserving methylation marks, both group 3
and group 4 MBs retain a stem-like epigenetic state and
their pattern of gene expression is more consistent with
progenitor and undifferentiated cells than cells with SHH-
and WNT-activated MBs [49]. Genes participating in
chromatin remodeling, such as KDM6A and ZMYM3, are
located on the X chromosome, explaining the higher
prevalence of group 3 and group 4 MBs in males [47].
The mutual theme of altered epigenetic regulation in
tumorigenesis across group 3 and group 4 tumors (Fig. 2b
and 3b) emphasizes the potential utility of drugs targeting
dysregulated epigenetic modifiers, with promising in vitro
results [50].
Another hallmark of non-WNT/non-SHH MBs is the
elevated expression of OTX2, a target of TGFβ signaling.
OTX2 amplification in group 3 MBs is mutually exclu-
sive to MYC amplification and is also routinely found in
group 4 MBs [6, 28]. OTX2 regulates cell cycle, drives
proliferation, inhibits cellular differentiation, and has
been associated with MB development [51]. Overexpres-
sion and knockdown of OTX2 are associated with al-
tered expression levels of several polycomb genes (EED,
SUZ12, and RBBP4) and genes encoding H3K27
demethylases (KDM6A, KDM6B, JARID2, and KDM7A)
[52]. Additionally, OTX2 targets EZH2 that could be
pharmacologically manipulated and is a potential target
especially for patients with hematological malignancies
[53]. Transcriptional profiling identified an elevated ex-
pression of a photoreceptor program in Group 3 MBs,
well characterized in the retina [32]. OTX2 transactiva-
tion contributes to the regulation of transcription factors
NRL and CRX, acting as master regulators of the
photoreceptor-specific program. Both genes are required
for tumor maintenance while the target of NRL, the pro-
tein BCL-XL, is necessary for tumor cell survival.
Anti-BCL therapy may serve as a rational therapeutic
target in this subset of group 3 MBs [54].
Approximately 20% of group 3 cases involve copy
number alterations in TGFβ pathway genes, including
the deletion of pathway inhibitors (CD109, FKBP1A,
SNX6) and amplification of regulators (ACVR2A,
ACVR2B, TGFBR1); thus, TGFβ signaling may represent
a rational target for personalized therapy [6, 28].
Notch-mediated signaling pathway plays a critical role
in CNS development, stem cell maintenance, and differ-
entiation of cerebellar granule neuron precursors; modu-
lates epithelial-to-mesenchymal transition; and has been
Table 1 Frequent genetic alterations in group 3 MBs according to [6, 12, 28, 38, 40, 113] (Continued)
Percentage
of patients
Gene/
chromosome
Modification Gene name Gene
location
Gene function
overexpression
3 FKBP1A Deletion FK506 binding protein 1A 20p13 TGF-β signaling
3 CDK6 Amplification Cyclin-dependent kinase 6 7q21.2 Cell cycle
2 ACVR2A Amplification Activin A receptor type 2A 2q22.3-
q23.1
TGF-β signaling
2 TGFBR1 Amplification Transforming growth factor beta receptor 1 9q22.33 TGF-β signaling
2 BRCA2 Mutation BRCA2, DNA repair associated 13q13.1 Genome maintenance
1 ACVR2B Amplification Activin A receptor type 2B 3p22.2 TGF-β signaling
1 E2F5 Amplification E2F transcription factor 5 8q21.2 Transcriptional regulation
– FOXG1 Overexpression Forkhead box G1 14q12 Transcriptional regulation
– IMPG2 Overexpression Interphotoreceptor matrix proteoglycan 2 3q12.3 Proteoglycan
– GABRA5 Overexpression Gamma-aminobutyric acid type A receptor alpha5
subunit
15q12 Neurotransmission
– EGFL11 Overexpression Eyes shut homolog (Drosophila) 6q12 Cell signaling
– NRL Overexpression Neural retina leucine zipper 14q11.2-
q12
Transcriptional regulation
– MAB21L2 Overexpression Mab-21 like 2 4q31.3 TGF-β signaling, neural
development
– NPR3 Overexpression Natriuretic peptide receptor 3 5p13.3 Natriuretic peptide metabolism
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Table 2 Frequent genetic alterations in group 4 MBs according to [6, 12, 28, 38, 40, 113]
Percentage
of patients
Gene/
chromosome
Modification Gene name Location Function
86 17q Mainly gain – – –
79 17p Mainly loss – – –
54 7q Mainly gain – – –
50 8p Loss – – –
43 7p Mainly gain – – –
43 8q Loss – – –
32 11p Loss – – –
28 11q Mainly loss – – –
21 X Loss – – –
17 PRDM6 Amplification,
overexpression
PR/SET domain 6 5q23.2 Chromatin modulation
10 SNCAIP Tandem duplication Synuclein alpha interacting protein 5q23.2 Chromatin modulation
9 GFI1B Amplification,
overexpression, deletion
Growth factor independent 1B
transcriptional repressor
9q34.13 Transcriptional regulation
8 DDX31 Deletion DEAD-box helicase 31 9q34.13 RNA metabolism
8 MYC Amplification MYC proto-oncogene, bHLH
transcription factor
8q24.21 Transcriptional regulation
8 CHD7 Mutation Chromodomain helicase DNA binding
protein 7
8q12.2 Chromatin modulation
8 DDX31 Mutation DEAD-box helicase 31 9q34.13 RNA metabolism
7 KDM6A Mutation Lysine demethylase 6A Xp11.3 Chromatin modulation
6 KBTBD4 Mutation Kelch repeat and BTB domain
containing 4
11p11.2 Ubiquitination of target substrates
6 KMT2C Mutation Lysine methyltransferase 2C 7q36.1 Chromatin modulation
6 ZMYM3 Mutation Zinc finger MYM-type containing 3 Xq13.1 Chromatin modulation
6 OTX2 Amplification Orthodenticle homeobox 2 14q22.3 Transcriptional regulation
6 MYCN Amplification MYCN proto-oncogene, bHLH
transcription factor
2p24.3 Transcriptional regulation
5 KDM4C Mutation Lysine demethylase 4C 9p24.1 Chromatin modulation
4 ZIC1 Mutation Zic family member 1 3q24 Transcriptional regulation
4 CDK6 Amplification Cyclin-dependent kinase 6 7q21.2 Cell cycle
3 FLG Mutation Filaggrin 1q21.3 Matrix protein
3 KMT2D Mutation Lysine methyltransferase 2D 12q13.12 Chromatin modulation
3 TBR1 Mutation T-box, brain 1 2q24.2 Transcriptional regulation
3 TERT Mutation Telomerase reverse transcriptase 5p15.33 Genome maintenance
3 GFI1 Amplification,
overexpression
Growth factor independent 1
transcriptional repressor
1p22.1 Transcriptional regulation
3 CCND2 Amplification Cyclin D2 12p13.32 Cell cycle
3 CTNNB1 Low level amplification Catenin beta 1 3p22.1 Wingless signaling
3 CTDNEP1 Mutation CTD nuclear envelope phosphatase 1 17p13.1 Metabolism of fatty acids
3 KDM1A Mutation Lysine demethylase 1A 1p36.12 Chromatin modulation
3 KDM5A Mutation Lysine demethylase 5A 12p13.33 Chromatin modulation
3 PIK3CA Mutation Phosphatidylinositol-4,5-bisphosphate
3-kinase
catalytic subunit alpha
3q26.32 Cell signaling
2 ATM Mutation ATM serine/threonine kinase 11q22.3 Genome maintenance
2 BRCA2 Mutation BRCA2, DNA repair associated 13q13.1 Genome maintenance
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implicated in MB disease etiology [55]. Mutations in
Notch signaling genes have been described in group 3
MBs [6], with especially elevated expression of NOTCH1
in spinal metastases [56]. Somatic copy number varia-
tions in group 4 MBs affect regulators of the NF-κB sig-
naling pathway, such as deletions of NFKBIA and USP4,
providing an opportunity for a rational targeted treat-
ment [28].
We summarize the most frequent genetic aberrations
of group 3 MBs in Table 1 and group 4 MBs in Table 2.
Tumor proteome analysis defines novel potentially
targetable signaling pathways
Both group 3 and group 4 MBs are characterized by
abundant within-subgroup genetic heterogeneity. The
low rate of recurrent lesions sets a challenge for success-
ful therapy development. Moreover, it is difficult to infer
phenotypes based on genomic data only; thus, global
proteome and phosphoproteome profiles may uncover
yet unknown subgroup-specific biological processes [43,
44, 57]. A recent phosphoproteomic comparison re-
vealed profound divergence in post-transcriptional regu-
lation and differential kinase activity between group 3
and group 4 samples: in group 3, the PDHK, CLK, and
CK2 kinase families, while in group 4 MBs, the kinases
downstream of the RTK-GPCR axis were primarily
enriched. The study identified aberrant RTK signaling as
a unifying feature of group 4, with a potentially pivotal
role of ERBB4 and SRC signaling in MB development
[44]. Another tumor proteome analysis underlies the
limited number of potentially targetable pathways; differ-
ent transcriptional patterns from untreated SHH, group
3, and group 4MB samples converged into only two
protein-signaling profiles. The first profile resembled
MYC-like signaling, encompassing all of the
SHH-activated and majority of group 3 samples. The
other protein profile consisted of the rest of group 3 and
the bulk of group 4 tumors, displaying DNA damage/
apoptosis/neuronal signaling [58].
Elevated MYC-expression is a discriminatory feature
of a subset of group 3 tumors. Some group 3 MBs are
characterized with an increased post-translational activa-
tion of MYC even in the absence of MYC amplification
and are linked to the elevated expression of kinases,
such as PRKDC, providing targets for future therapies
[43]. HMGA1 is a stem cell phenotype regulator that
targets MYC and is also targeted by MYC, and plays a
role in cell growth and invasion in cancer. In a prote-
omic analysis, HMGA1 isoforms a and b showed ele-
vated expression in Group 3 MBs associated with poor
outcome [57].
In summary, proteomic platforms complement cytogen-
etic, transcriptomic, and mutation-based data and expand
translational opportunities. Data integration on multiple
levels yields a more complete understanding of cancer
biology for the sake of novel therapeutic strategies.
Prognostic biomarkers of survival
Within each MB subgroup, additional subtypes can be
identified with distinct biological backgrounds and clin-
ical outcomes [5, 30, 31]. Subgroup-specific markers of
prognosis may present the most beneficial route to avoid
over- or undertreatment [14]. The proposed four cat-
egories consist of low-, standard-, high- and very
high-risk non-WNT/non-SHH MBs for non-infant (age
3–17 years) patients [25].
Table 2 Frequent genetic alterations in group 4 MBs according to [6, 12, 28, 38, 40, 113] (Continued)
Percentage
of patients
Gene/
chromosome
Modification Gene name Location Function
2 FAT1 Mutation FAT atypical cadherin 1 4q35.2 Cell signaling
2 MED12 Mutation Mediator complex subunit 12 Xq13.1 Chromatin modulation
2 SMARCA4 Mutation SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin,
subfamily a, member 4
19p13.2 Chromatin modulation, SWI/SNF
nucleosome-remodeling complex
2 ACVR2B Amplification Activin A receptor type 2B 3p22.2 Cell signaling
2 SEMA3D Amplification Semaphorin 3D 7q21.11 Axon guidance during development
– FOXG1 Overexpression Forkhead box G1 14q12 Transcriptional regulation
– KCNA1 Overexpression Potassium voltage-gated channel
subfamily A member 1
12p13.32 Voltage-gated potassium (K+) channel
– EOMES Overexpression Eomesodermin 3p24.1 Transcriptional regulation
– KHDRBS2 Overexpression KH RNA binding domain containing,
signal transduction associated 2
6q11.1 RNA metabolism
– RBM24 Overexpression RNA binding motif protein 24 6p22.3 RNA metabolism
– UNC5D Overexpression Unc-5 netrin receptor D 8p12 Cell adhesion, axon guidance
– OAS1 Overexpression 2′-5′-Oligoadenylate synthetase 1 12q24.2 Cellular innate antiviral response
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The low-risk (> 90% survival) group consists of
non-metastatic group 4 patients with chromosome 11
loss (approximately one-third) and/or gain of whole
chromosome 17 (approximately 5%). The standard-risk
(75–90% survival) population includes patients with
non-metastatic group 3 without MYC amplification and
non-metastatic group 4 without chromosome 11 loss.
The high-risk (50–75% survival) cohort consists of
metastatic group 4 patients, and very high-risk (< 50%
survival) refers to metastatic group 3 patients with MYC
amplification [8, 14, 59].
Risk evaluation of non-metastatic but MYC-amplified
group 3 tumors with an LCA histology or isochromo-
some i17q or group 4 MBs with anaplastic histology re-
quires further clarifications [8] (Fig. 2a, 3a). The
Medulloblastoma Advanced Genomics International
Consortium identified good outcome regardless of the
presence of metastases in a noteworthy portion of group
4MB patients with loss of chromosome 11 (15%) and/or
gain of whole chromosome 17 (5%) [14]. Therapy
de-escalation in these subtypes requires prospective clin-
ical investigations.
Emerging risk stratification models
Based on the utilized patient populations (children vs.
children and adults) and statistical methods, divergent
new stratification schemes started to emerge. A recent
methylation pattern-based stratification split Group 3
and Group 4 children into high-risk (HR) and low-risk
(LR) categories with dramatically different survival rates
(group 3, 10-year OS of 22% in HR vs. 69% in LR; group
4, 36% in HR vs. 72% in LR). Group 4 HR was character-
ized by frequent metastatic disease, residual disease after
surgery, frequent GFI1 mutations, and high rates of
i17p, compared to group 4 LR which was characterized
by MYCN amplifications. Group 3 HR was associated
with frequent MYC amplification, GFI1 mutations, pre-
dominance in males, and LCA histology, while the oc-
currence of group 3 LR was most frequent in infants
and was associated with metastases. Shared biological
signature between group 3 and group 4 tumors
prompted their combination in the stratification algo-
rithm that outperformed the current risk stratification
models. In addition, a novel biomarker, loss of chromo-
some 13, was identified as an independent risk factor in
non-WNT/non-SHH cohorts [30] (Fig. 2a and 3a).
Another methylation-based study divided group3/
group4 MBs into eight subtypes, assigning MYC-driven
samples to subtype II [6]. Clustering group 3 MBs based
on post-translational modifications resulted in two sub-
types, out of which G3a corresponded to the earlier
identified subtype II [6], representing the MYC-activated
group 3 MBs.
Expression- and methylation-based integrated cluster-
ing divided group 3 and group 4 tumors into six sub-
types altogether; group 3α and group 3β yielded equal
survival outcomes. Group 3α patients were younger with
frequent metastases, while group 3β was represented by
usually slightly older, non-metastatic patients with a high
frequency of GFI1 and GFI1B oncogene activation,
OTX2 amplification, and loss of DDX31. Group 3γ had
the worst prognosis, with repeated MYC amplification
and i17p enrichment [31] (Fig. 2a). Group 4α was
enriched for MYCN amplification, group 4β for SNCAIP
duplications, and group 4γ mainly for CDK6 amplifica-
tions; nevertheless, the rate of metastatic spread or sur-
vival was not different across group 4 subtypes [31]
(Fig. 3a).
Well-planned collaborative prospective studies will be
necessary to reach a consensus among emerging risk
stratification algorithms.
Preclinical models of group 3 MBs reveal
potential therapeutic targets
Group 3 MBs mostly develop in the fourth ventricle as
small primary tumors with early dissemination [60] and
appear to originate from at least two different cell types;
tumors resembling human MYC-enriched group 3 de-
velop from cerebellar progenitors with stem-like proper-
ties after an enforced expression of MYC [61, 62] or
from GABAergic neuronal progenitors [63]. MYC family
genes encode transcription factors that form heterodi-
mers to activate or repress downstream signaling. The
Myc-Miz1 (a Pox virus and zinc finger (POZ) domain
transcription factor) complex represses the transcription
of negative cell cycle regulators [64] and activates a gene
repression program responsible for maintaining a
stem-like phenotype. Target genes of Myc-Miz1 are re-
pressed in murine models of group 3 MBs, and the dis-
ruption of Myc-Miz1 inhibits group 3 tumor formation;
thus, the critical interaction between Myc and Miz1 rep-
resents a defining hallmark of group 3MB development
[65]. In the same cerebellar progenitor cells, MycN
forms complexes with Miz1 less efficiently and induces
instead sonic hedgehog-activated (SHH) MBs [65].
MYC is a poor target of small molecule inhibition;
therefore, alternative strategies are necessary to target
MYC transcription or MYC target genes. Spontaneous
animal models recapitulating group 3MB development
are lacking. Several orthotopic murine models of
MYC-driven group 3 oncogenesis have attempted to
clarify MYC involvement in MB tumor initiation, main-
tenance, and progression and provide models for new
therapeutic strategies [61, 62, 66]. Conditional expres-
sion of MYC and loss of TRP53 in a murine model in-
duced different tumor types in situ from various
multipotent embryonic cerebellar progenitor cells [63].
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MYC overexpression coupled with TRP53 inactivation
resulted in tumors that resemble human MB exhibiting
an LCA histology with similarity in gene expression sig-
natures. The generated tumors were enriched for genes
targeted by PI3K and mTOR inhibitors, indicating the
importance of PI3K/mTOR signaling in MYC-driven
MBs [61]. Drug screening within this model identified
histone deacetylase inhibitors (HDACIs, such as
LBH-589) demonstrating synergistic activity with phos-
phatidylinositol 3-kinase inhibitors (PI3KI) via activating
the expression of the FOXO1 tumor suppressor [67].
Another murine model utilizing human neural stem and
progenitor cells harboring transformed c-MYC,
dominant-negative p53, and constitutively active AKT
and hTERT revealed tumor sensitivity to
cyclin-dependent kinase (CDK) inhibitors, such as pal-
bociclib [66]. Based on proteomics, a subset of group 3
MBs was identified with increased post-translational ac-
tivation of MYC even in the absence of MYC-amplifica-
tions, with the potential role of the PRKDC kinase in
promoting MYC stability. PRKDC assists DNA
double-strand breaks repair through non-homologous
end-joining and in MYC-amplified group 3 cell lines;
both MYC and PRKDC protein were highly enriched.
The PRKDC inhibitor NU7441 preferentially sensitized
the MYC-amplified cell line D458 to radiation [43].
Bromodomain and extraterminal (BET)-containing
proteins facilitate gene transcription by recognizing side
chain acetylated lysine on open chromatin and have
been identified as novel potential targets of MYC or
MYCN transcription [68]. BET bromodomain inhibi-
tors of MYC-amplified MBs, such as compound JQ1, re-
duced in vitro cell proliferation and prolonged survival
in MYC-amplified MB xenografts, possibly through the
inhibition of BRD4 [69], a cofactor of MYC-dependent
transcription [68].
Based on gene set enrichment analyses, group 3
MBs are enriched in the folate and purine metabolism
pathways compared to group 4 MBs. The combined
application of the folate synthesis inhibitor peme-
trexed and nucleoside analog gemcitabine inhibited
cellular growth in vitro and increased the survival of
mice bearing cortical group 3 implants overexpressing
MYC-protein. Nonetheless, resistance developed in all
cases [70].
The expression of GABAA receptor α5 subunit gene
(GABRA5) is elevated in MYC-driven group 3 MBs [40].
Benzodiazepines function as receptor ligands of GABAA
receptor α5 subunit, but they also have undesirable toxic
side effects, such as respiratory depression in mouse
xenograft models [33]. High-throughput localized intra-
tumor drug delivery of a new benzodiazepine deriva-
tive, KRM-II-08, demonstrated higher in vivo activity
compared to cisplatin in nude mouse xenografts [71].
A model investigating angiogenesis found significantly
elevated VEGFA mRNA expression in Group 3 compared
to the other subgroups, strongly associated with reduced
overall survival. Gene enrichment analysis using the xeno-
graft mouse models of group 3MB identified five potential
driver genes linked to angiogenesis, of which RNH1,
SCG2, and AGGF1 expression were associated with de-
creased survival. The clinical significance of these genes
requires further analysis, while VEGFA already provides a
druggable target, suggesting that anti-vascularization
therapies may be a potential route to treat group 3 MBs.
Finally, dynamic susceptibility-weighted (DSC) MRI and
susceptibility-weighted imaging (SWI) were able to iden-
tify three distinct organization patterns in the tumor vas-
cular architecture associated with survival, thus presenting
a probable clinically relevant biomarker of survival [72].
CD47 is a membrane protein that functions as an
anti-phagocytic cell surface ligand that blocks macro-
phages from destroying tumor cells [73]. CD47 is
expressed on the cell surface of malignant pediatric
brain tumors [74]. CD47 binds and activates the inhibi-
tory signal regulatory protein-a (SIRPα) on the cell sur-
face. Humanized anti-CD47 antibody, Hu5F9-G4,
blocked CD47-SIRPα interactions efficiently and demon-
strated high therapeutic efficacy in vitro and in
patient-derived xenograft models of group 3 MBs. Sys-
temic treatment reduced the growth of both primary tu-
mors and leptomeningeal metastases. Intraventricular
administration of Hu5F9-G4 was associated with in-
creased survival in xenograft models with metastases, al-
though this type of drug administration was ineffective
on primary tumors [74].
In summary, most preclinical in vitro and murine
models resemble MYC-activated MBs, and the field lacks
adequate representation of heterogeneity within group 3
tumors. In fact, all of existing group 3MB cell lines are
MYC amplified [35] compared to the presence of MYC
amplifications in 17% of group 3 patients [28]. Model
systems focusing on mechanisms of non-MYC-amplified
group 3 tumorigenesis are in great demand.
Preclinical models of group 4 MBs are limited
Group 3 and group 4 MBs generally develop in similar
locations [63], although differences of expression pat-
terns imply distinct cellular compartment of origin [13,
28]. A study investigating the regulatory role of pre-
dicted super-enhancers localized the expression of a
master regulator exclusive to group 4 MBs (the tran-
scription factor LMX1A) in neurons of the nuclear tran-
sitory zone, possibly originating from the upper rhombic
lip of the cerebellum [75]. Proteogenomic studies impli-
cated aberrant ERBB4 and SRC signaling as hallmarks of
group 4 MBs [44]. Constitutive activation of SRC along
with a forced expression of a dominant negative form of
Menyhárt et al. Journal of Hematology & Oncology           (2019) 12:29 Page 11 of 17
p53 in a murine model resulted in tumors in the poster-
ior cerebellum and dorsal hindbrain, a typical location of
group 4 MBs, with a gene expression pattern similar to
group 4 tumors [44]. Consistently, ERBB4 and phos-
phorylated SRC were detectable in the nuclear transitory
zone of the murine cerebellum at embryonic day 13, but
absent from granule neuron progenitors on postnatal
day 7 [44]. In another murine model, the enforced ex-
pression of MYCN under the GLT1 promoter or glial fi-
brillary acidic protein-positive (GFAP+) neonatal cells
induced MB development expressing KCNA1, a known
marker of group 4 tumors [76].
In summary, preclinical models recapitulating group 4
MB development and progression are mostly lacking.
There is only a single pair of cell lines unambiguously
classified as group 4, derived from the same patient:
CHLA-01-MED and CHLA-01R-MED [35]. Separate
models of the mutually exclusive MYCN-, SNCAIP-, or
CDK6-driven tumorigenesis are greatly needed. Preclin-
ical systems modeling the effects of PRDM6 activation,
present in 17% of group 4 patients, would promote our
understanding of group 4 tumorigenesis. Given the large
portion of patients (~ 40%) diagnosed with group 4 MBs,
it is of utmost importance to identify common molecu-
lar mechanisms and therapy targets, especially for pa-
tients with high-risk disease. Integrative proteogenomic
approaches might provide promising means to unravel
novel targetable pathways [44].
Risk-specific treatment strategies of non-WNT/
non-SHH MBs
Medulloblastoma treatment strategy is multimodal, in-
cluding maximal safe resection, radiotherapy, and
chemotherapy. The treatment type and intensity are de-
fined by age at diagnosis, metastatic status, and extent of
surgical resection [77, 78]. The extent of disease deter-
mines the risk of recurrence, while patient age restricts
the treatment options, as young children (< 3 years of
age) are particularly vulnerable to radiation therapy.
Patients with minimal tumor residue have a better
long-term outcome, especially when metastases are ab-
sent [78, 79]. With the help of modern imaging tech-
niques during surgery, gross total (no remaining tumor
residue) or near-total (diameter of residue is less than
1.5 cm) resection is achieved in the majority of patients.
When accounting for molecular subgroups, a study
based on 787 patients identified a progression-free sur-
vival benefit for gross total resection over subtotal resec-
tion (tumor residue larger than 1.5 cm), but no benefits
in the overall survival. Improvement was most notice-
able for group 4 patients, for whom gross total resection
increased the progression-free survival compared to that
of subtotal resection, especially in the case of metastatic
disease [16]. Thus, maximum safe resection provides the
best outcome without being overly aggressive by pre-
serving the neurologic integrity, especially when the risk
of neurologic morbidity is high.
Based on these factors, patients can be divided into
two different treatment groups. Children older than 3
years with total or near-total resection and no metastatic
dissemination are classified as average or standard risk,
while patients with suboptimal tumor resection, dissem-
ination, or metastasis and/or LCA histology are treated
as having high-risk disease [77]. The LCA histology is
enriched in SHH TP53 mutant and high-risk group 3 tu-
mors and is associated with a poor outcome across all
age groups, with a 5-year overall survival (OS) as low as
22% in infants [10]. Risk stratification also determines
the intensity of craniospinal irradiation [80]. The average
risk, non-infant patients are treated with 23.4 Gy cra-
niospinal irradiation with a boost of 55 Gy to the tumor
bed in the posterior fossa, followed by adjuvant chemo-
therapy [81]. High-risk patients receive a dose of 36–39
Gy, a boost of 55 Gy to the tumor bed, and adjuvant
chemotherapy [82]. Typical chemotherapy regimens
consist of cisplatin/carboplatin-vincristine-cyclophospha-
mide combinations. A prospective study of average-risk
group 4 patients aged 3–17 years treated with surgery,
irradiation, and chemotherapy found excellent 5-year
progression-free survival (95.9% and 88.7%) for patients
treated by two different protocols [17].
Infants under the age of 3 years require delayed radi-
ation therapy and are preferably treated by multiagent
chemotherapy. The tested chemotherapy regimens in-
clude vincristine, cyclophosphamide, etoposide, and cis-
platin followed by autologous hematopoietic cell rescue
(CCG-99703) and methotrexate (intravenous and intra-
ventricular), vincristine, cyclophosphamide, and carbo-
platin (HIT-SKK’92) [83, 84]. This approach provides a
better outcome for children with gross total resection
with an absence of metastatic dissemination compared
to patients with residual or metastatic disease [84–86].
Delay of radiation therapy may be particularly favorable
in young children with an MB of desmoplastic/extensive
nodular histology; thus, the advantage of deferred radio-
therapy is histological subtype-specific as well [87]. Fur-
thermore, radiation avoidance in infants reduces
treatment-related neurocognitive deficits [88].
In adults, due to the relatively low incidence of MBs
(< 1% of all adult CNS tumors), there is no accepted
standard of care. The current treatment strategy involves
craniospinal irradiation given mostly post-resection as
well as occasional chemotherapy mainly for high-risk
disease, both with unknown outcomes [89, 90].
The clinicopathologic feature-based risk stratification
fails to consider heterogeneity within standard- and
high-risk patients. Nonetheless, an exciting transform-
ation is ongoing with the integration of molecular data
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into MB classification [15]. Ongoing clinical trials inves-
tigate the optimal clinical and molecular risk-directed
therapy in a subtype-specific manner in non-WNT/
non-SHH MBs, although rational targeted approaches
are still absent in existing trials. A phase II trial
NCT01878617 with a primary completion date of 2023
contains a treatment arm that investigates the value of
new chemotherapy agents (pemetrexed and gemcitabine)
supplemented to standard treatment in intermediate-
and high-risk patients and the effects of reduced-dose
cyclophosphamide as first line in standard risk of
non-WNT/non-SHH MBs.
Therapy optimization awaits solutions for a number of
ongoing challenges. High-risk MBs have been a
neglected entity in international clinical trials. It is of
top priority especially for very high-risk patients (such
as group 3 with MYC amplifications) to clinically evalu-
ate substances previously determined as effective in pre-
clinical studies, such as histone deacetylases and PI3K
inhibitors. Therapies are also in demand for metastatic
patients. Moreover, prospective studies are required to
validate the clinical utility of low-risk biomarkers, par-
ticularly in metastatic tumors, and clinical trials are
needed to test therapy de-escalation in low-risk
populations.
Metastatic non-WNT/non-SHH medulloblastomas
MBs have the tendency to disseminate early via the cere-
brospinal fluid (CSF) in the leptomeningeal space in
three biologically distinct forms: free-floating tumor cells
in the CSF, nodular and laminar metastases, and the last
with the shortest survival [91]. About 45% of group 3
and 40% of group 4 patients have disease dissemination
at the time of diagnosis, frequently at distant locations,
and dissemination is independent of the type of therapy
[23]. Group 3 metastases are mostly laminar compared
to the more nodular pattern in metastatic group 4 pa-
tients, and suprasellar metastases are highly specific to
group 4 MBs, suggesting different molecular mecha-
nisms of disease spread across subtypes [92]. Disease
dissemination occurs in the central nervous system in
half of the patients, and extraneural metastases (ENMs)
are located frequently in the bone (84%), bone marrow
(27%), lymph nodes (15%), and liver and lung (6–6%)
[93]. Metastatic patients are treated for a high-risk dis-
ease, but most patients experience relapse and disease
spread regardless of therapy. The prognosis is particu-
larly poor for group 3 patients with MYC or MYCN am-
plifications; nevertheless, not all group 3 metastatic
patients have a uniformly poor outcome [94].
The outlook for previously irradiated patients with MB
recurrence is grim in spite of the multitude of treatment
options including surgery, radiation, high-dose chemo-
therapy, and participation in clinical trials [95–97].
Overall, relapse is responsible for 95% of MB-associated
deaths, emphasizing the need for more competent ther-
apies [3]. To prevent disease spread and recurrence, we
must understand the molecular mechanisms regulating
migration and invasion better.
Targetable somatic mutations, assessed by multire-
gional biopsies, are spatially heterogeneous even within
primary tumors [98]. Even though metastases maintain
the subgroup identity of their corresponding primary le-
sions, primary tumors and metastatic clones are substan-
tially different as a consequence of clonal selection.
Nevertheless, the preserved subgroup identity suggests a
different cellular origin across group 3 and group 4 MBs
[99–101].
Molecular pathways involved in self-renewal and metas-
tases are starting to emerge. Notch signaling has been
linked to medulloblastoma development [55], with a par-
ticular focus on NOTCH1 driving group 3MB metastases
[56]. Spinal metastases expressed higher levels of
NOTCH1 and Notch1 pathway-regulated genes (including
genes responsible for motility, migration, and adhesion,
such as TWIST1) compared to primary tumor sites, sug-
gesting a distinct population of MB cells that are able to
metastasize. NOTCH1+ cells also represent a population
of stem cells implicated in self-renewal and maintenance
of the primary tumors. Mice bearing group 3 MBs devel-
oped lower rates of spinal metastases after treatment with
a NOTCH1-blocking antibody anti-NRR1, supporting the
importance of the Notch1 pathway as a therapy target
[56]. BMI1 has been implicated in MB pathogenesis and
poor outcome [102] and is a direct downstream target of
NOTCH1 and TWIST. NOTCH1 silencing downregulated
MYC expression, while silencing TWIST1 resulted in
MYC levels comparable with controls, suggesting
different regulatory models of NOTCH1-MYC and
NOTCH1-TWIST1-BMI1 axes [56].
Overexpression of PRUNE1 promotes motility and
metastatic processes in solid tumors and is associated
with poor survival [103, 104]. Protein products of
PRUNE1 and NME1 are preferentially expressed during
brain development [105] and form a protein complex
[106]. In metastatic group 3, MBs PRUNE1 enhanced
TGFβ signaling through the upregulation of OTX2 and
SNAIL and suppression of PTEN, and induced
epithelial-to-mesenchymal transition [107]. Disrupting
the interaction between PRUNE1 and NME1 with a
competitive permeable peptide in orthotropic xenografts
inhibited primary tumor growth and cancer spread;
moreover, a small molecule PRUNE1 inhibitor, AA7.1,
impaired MB progression and dissemination in xeno-
grafts [107]. MBs and leptomeningeal metastases contain
abundant and activated IGF1R, IGF1, and IGF2 com-
pared to normal cerebellar tissue [108], promoting sur-
vival and proliferation of granule neuron precursors
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[109]. In MYC-amplified MB cells, IGF1 induces migra-
tion; thus, the bioavailability of IGF1 from the leptomen-
ingeal surface may promote migration and metastatic
growth. Targeting IGF1R may represent a feasible ap-
proach to prevent spread within high-risk MBs [110].
Upregulated PDGFRA and downstream members of the
RAS/MAPK signaling pathways have also been identi-
fied in metastases, associated with in vitro migratory be-
havior [111].
Preclinical models of anti-metastatic treatment are
scarce. In a recent study, humanized anti-CD47 anti-
body, Hu5F9-G4, blocked CD47-SIRPα interactions that
halt macrophages from destroying tumor cells. Systemic
Hu5F9-G4 administration reduced the growth of both
primary tumors and leptomeningeal metastases in
Group 3MB xenografts [74]. Intraventricular drug ad-
ministration increased survival in xenografts with metas-
tases, although it was ineffective on primary tumors.
Additionally, Hu5F9-G4 eliminated CD15+
tumor-initiating cells significantly, suggesting to be a po-
tential treatment against stem cells to prevent relapses
[74].
Collection of clinical samples from primary lesions
and metastases would facilitate the exploration of func-
tional heterogeneity within primary tumors and target-
able signaling pathways in metastases, albeit group 3 and
group 4 MBs usually relapse as metastases, making the
resampling difficult. Despite emerging molecular mecha-
nisms of self-renewal and disease spread, clinically rele-
vant substances targeting metastases are just starting to
emerge. Eliminating treatment-resistant stem-like cells
could provide a feasible approach to treat high-risk MBs
in the future [112], although cell populations responsible
for treatment resistance are not fully explored.
Conclusions
Molecular synthesis suggests that despite tumor hetero-
geneity, rare molecular events converge on a limited
number of potentially targetable signaling pathways, and
the dysregulated epigenetic machinery offers rational tar-
gets for drug development across subgroups.
Current preclinical models explore only a thin layer of
phenotypes in high-risk tumors (MYC- or MYCN-ampli-
fied group 3 MBs), but additional models are needed to
analyze mechanisms of tumorigenesis. Samples from re-
lapses compared to primary tumors would also provide
a wealth of information, but recurrent MBs are rarely
resected.
Nonetheless, unknown territories are still abundant,
especially within non-WNT/non-SHH tumors. Mo-
lecular stratification is not conclusive, as intermediate
subgroups are emerging. Reliable methods, accessible
for daily clinical application, are sought after to assess
subgroup (and subtype) affiliation, as the correct
classification of patients is needed to bring a revolu-
tion in systemic treatment. Molecularly stratified
treatment options are limited, and targeted therapies
are only in preclinical development. The development
of rational treatment approaches especially for
high-risk and metastatic non-WNT/non-SHH patients
is of first priority to suppress stagnant survival rates
of the past decades.
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